All In Biotech

Drug Trial Radar · NCT04419272

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits: a Randomized, Double-blind, Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 226 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

226

Planned (sponsor's estimate)

Start

Aug 14, 2023

Primary completion

May 31, 2028

Study completion May 31, 2028

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
Collaborators
VA New York Harbor Healthcare System; Portland VA Medical Center; Miami VA Healthcare System; VA Boston Healthcare System
First posted
Jun 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy. In this study, participants will be assigned randomly (i.e., by flip of a coin), to a group that takes MPH and a group that takes a placebo (sugar pill). Participants will not know the group to which they have been assigned. Tests of attention and memory will be completed before taking the study pills and at Week 8. All participants will then have the option of taking MPH for the next two months, and attention and memory will be tested again at Week 16. The study will determine whether methylphenidate is helpful for the treatment of attention and memory problems in adults with epilepsy, and whether the medication is safe and beneficial when taken over an extended time period.

Conditions

  • Epilepsy

Interventions

  • MethylphenidateDrug

    10mg twice per day, at 8am and 12pm, for one week, then increased to 20mg twice daily, at 8am and 12pm, for the next 7 weeks during the double-blinded period.

  • PlaceboOther

    When assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 8 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.

  • MethylphenidateDrug

    During the open-label extension phase, dosing will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Conners Continuous Performance Test (CPT), Following Placebo vs. MethylphenidateTime frame: Week 8

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Miami VA Healthcare System, Miami, FL

    Miami, Florida · Recruiting

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

    Boston, Massachusetts · Recruiting

  • VA NY Harbor Healthcare System, New York, NY

    New York, New York · Recruiting

  • VA Portland Health Care System, Portland, OR

    Portland, Oregon · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.